VBI Vaccines Inc. VBIV
Set alert
At close · Aug 7
- Open
- 0.0851
- Prev close
- 0.0653
- Mkt cap
- 1.87M
- Vol
- 27.93M
- Avg vol
- 8.54M
- EPS
- -3.54
- P/E
- -0.02
- Div yield
- 0.00%
More statistics
- Low
- 0.0574
- High
- 0.0866
- Forward P/E
- -0.23
- Beta
- 2.17
- Short ratio
- 1.57
- Inst. own
- 13.04%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 12, 2024
- 50-d avg
- 0.477313
- 200-d avg
- 0.582543
- 1y target
- 5.00
Key statistics
- Market cap
- 1.87M
- Enterprise value
- 38.93M
- Trailing P/E
- 0.00
- Forward P/E
- -0.23
- PEG ratio
- 0.00
- Price / sales
- 0.20
- Price / book
- 0.00
- EPS (TTM)
- -3.54
- Beta
- 2.17
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 9.41M
- Revenue growth
- 150.30%
- Free cash flow
- -29.10M
- Total cash
- 12.60M
- Total debt
- 50.71M
- Return on equity
- -419.59%
- Shares outstanding
- 28.68M
- Short % of float
- 1.16%
- 50-day average
- 0.477313
- 200-day average
- 0.582543
Analyst view
Consensus: buy
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 12, 2024
Expected Aug 12, 2024. Consensus EPS estimate -0.32.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 12, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | -0.53 | — | — | — |
| Apr 1, 2024 | Dec 1, 2023 | -0.22 | — | — | — |
| Nov 14, 2023 | Sep 1, 2023 | -0.14 | — | — | — |
| Aug 14, 2023 | Jun 1, 2023 | -2.16 | — | — | — |
| May 15, 2023 | Mar 1, 2023 | -2.27 | — | — | — |
About VBI Vaccines Inc.
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vaccine immunotherapeutic candidate; VBI-1501, a prophylactic cytomegalovirus vaccine candidate; and VBI-2501 to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited, the National Research Council of Canada, and Coalition for Epidemic Preparedness Innovations. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- vbivaccines.com
News
- VBI Vaccines Issues Voluntary Nationwide Recall of all PreHevbrio Vaccine Due to Discontinuation of Company Operations
- Why Fortinet Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
- Dow Jumps Over 300 Points; US Trade Gap Narrows In June
- Why Is VBI Vaccines (VBIV) Stock Up 62% Today?
- Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- VBI Vaccines Announces Results of Annual General Meeting
- VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
- VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients
- VBI Vaccines Reports First Quarter 2024 Financial Results
- VBI Vaccines Reports Full Year 2023 Financial Results
Your note
Sign in to keep a note on VBIV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDERSON DAVID EVANDER | Officer | Conversion of Exercise of derivative security | Jun 13, 2019 | 148,209 |
| BAXTER JEFFREY ROYSTON | Chief Executive Officer | Purchase | Sep 29, 2019 | 608,255 |
| BEATTIE NELL | Officer | Purchase | Dec 2, 2021 | 68,200 |
| DEWILDE MICHEL | Director | Conversion of Exercise of derivative security | Jun 13, 2019 | 50,000 |
| DIAZ-MITOMA FRANCISCO | Officer | Purchase | Oct 3, 2019 | 0 |
| GILLIS STEVEN | Director | Purchase | Jul 9, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Perceptive Advisors Llc | 6.04% | 1,381,355 | 4.54M | Jun 29, 2023 |
| Blackrock Inc. | 0.49% | 112,145 | 368.96K | Jun 29, 2023 |
| Cambridge Investment Research Advisors Inc. | 0.44% | 100,368 | 330.21K | Jun 29, 2023 |
| Millennium Management Llc | 0.39% | 89,205 | 293.48K | Jun 29, 2023 |
| Morgan Stanley | 0.34% | 77,977 | 256.54K | Jun 29, 2023 |
| Geode Capital Management, LLC | 0.29% | 67,189 | 221.05K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| General American Investors Co | 0.27% | 62,583 | 205.90K | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 0.26% | 59,707 | 196.44K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.14% | 31,328 | 93.04K | May 30, 2023 |
| Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 0.11% | 26,245 | 77.95K | May 30, 2023 |
| Vanguard Russell 2000 Index Fund | 0.07% | 17,050 | 50.64K | May 30, 2023 |
| Fidelity Total Market Index Fund | 0.05% | 11,998 | 35.63K | May 30, 2023 |